New Research Released on FSD Pharma Inc. (HUGE-NASDAQ/HUGE-CSE)

Posted by Karen Goldfarb

March 11, 2020 at 2:27 PM

An Executive Informational Overview (EIO) is now available on FSD Pharma Inc. (HUGE-NASDAQ/HUGE-CSE), a specialty biotech pharmaceutical company focused on developing FDA-approved synthetic compounds targeting the endocannabinoid system (ECS) of the human body. The 68-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download FSD Pharma Inc. Report

Read More

Topics: Cannabis, fsd pharma, Endocannabinoid System (ECS), Palmitolylethonalamide (PEA), Prismic Pharmaceuticals, ultramicronized-PEA, fsd, SciCann Therapeutics, Solarvest BioEnergy Inc., FSD201, medical cannabis, Canntab Therapeutics Ltd, Huge Shops, Aura Health Inc.

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Topic